These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32754748)

  • 1. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
    Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.
    Brue T; Chanson P; Rodien P; Delemer B; Drui D; Marié L; Juban L; Salvi L; Henocque R; Raverot G
    Front Endocrinol (Lausanne); 2021; 12():745843. PubMed ID: 34690933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
    Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
    Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
    Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing somatostatin analog therapy in acromegaly: long-acting formulations.
    Gilroy JJ; James RA
    Treat Endocrinol; 2002; 1(3):149-54. PubMed ID: 15799207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
    Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
    Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
    Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
    Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
    Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
    Barkan AL; Burman P; Clemmons DR; Drake WM; Gagel RF; Harris PE; Trainer PJ; van der Lely AJ; Vance ML
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5684-91. PubMed ID: 16076947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.
    Ghigo E; Biller BM; Colao A; Kourides IA; Rajicic N; Hutson RK; De Marinis L; Klibanski A
    J Endocrinol Invest; 2009 Dec; 32(11):924-33. PubMed ID: 20009494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
    Neggers SJ; de Herder WW; Feelders RA; van der Lely AJ
    Pituitary; 2011 Sep; 14(3):253-8. PubMed ID: 21221818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of pharmacologic treatment in US patients with acromegaly.
    Broder MS; Chang E; Ludlam WH; Neary MP; Carmichael JD
    Curr Med Res Opin; 2016 May; 32(5):799-805. PubMed ID: 26609770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
    van der Lely AJ; Bernabeu I; Cap J; Caron P; Colao A; Marek J; Neggers S; Birman P
    Eur J Endocrinol; 2011 Mar; 164(3):325-33. PubMed ID: 21148630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
    Salvatori R; Nachtigall LB; Cook DM; Bonert V; Molitch ME; Blethen S; Chang S;
    Pituitary; 2010 Jun; 13(2):115-22. PubMed ID: 19898989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.